Pluronic F127 Micelles Co-encapsulating a Brachydin-Enriched Fraction and Curcumin: A Self-assembled Platform for Light-assisted Antileishmanial Activity
- 1Federal University of Maranhão , , ,
- 2Federal University of Paraná (UFPR) , , , ,
Abstract
This study developed an associative Pluronic F127-based formulation co-loaded with a brachydin-enriched fraction and curcumin (FBC) for preliminary light-assisted antileishmanial evaluation. The formulation showed high apparent active-material recovery after centrifugation and filtration, as estimated by HPLC-PDA. DLS analysis indicated a polydisperse colloidal profile, with an apparent mean hydrodynamic diameter of approximately 406.5 nm and a number-weighted smaller population centered at approximately 12.1 nm. FTIR data were consistent with formulation-related changes in the vibrational environment of the hydrophobic active materials, while AFM and SEM provided complementary morphological information on deposited or dried samples. Together, these data support an interpretative F127-based self-assembly model, without establishing a fully uniform colloidal population or a definitively resolved internal micellar architecture. In vitro cytotoxicity assays using GM07492A human lung fibroblasts indicated low basal cytotoxicity under dark conditions, whereas light exposure produced concentration-dependent viability reductions at higher formulation concentrations. Antileishmanial assays against Leishmania amazonensis promastigotes revealed a marked light-associated response, mainly in formulations containing the brachydin-enriched fraction. FB showed the highest potency under light exposure, with a formulation-based IC50 of 18.63 μg mL–1, whereas FBC showed an IC50 decrease from 72.74 to 34.33 μg mL–1. Thus, although FBC was not more potent than FB, it combined light-associated antileishmanial activity, high apparent active-material recovery, and favorable macroscopic formulation behavior. Because FB and FBC contain a brachydin-enriched fraction rather than purified individual brachydins, the biological responses should be interpreted as preliminary formulation-level effects. Further studies involving direct reactive oxygen species measurements, intracellular amastigote assays, formal selectivity analysis, fraction standardization, and long-term colloidal stability evaluation are still required before therapeutic efficacy can be inferred.
Related
- Deconvoluting the mode of action of antileishmanial aminopyrazoles through chemical mutagenesis
- Comparative study of niosomal nanoparticles encapsulating Artemisia aucheri and Artemisia sieberi extracts on Michigan Cancer Foundation-7 breast cancer cell proliferation: An in vitro study
- Mapping the antileishmanial structure-activity relationship of eugenol
- Reduced Peritoneal NRF2 Immunoreactivity in Encapsulating Peritoneal Sclerosis and Its Implications for Redox Homeostasis.
- GelMA‐Based Hydrogel Encapsulating Astragalus Polysaccharides and Umbilical Cord Mesenchymal Stem Cell Exosomes Promotes Full‐Thickness Skin Wound Healing
BibTeX
@article{lima2026pluronic,
title = {{Pluronic F127 Micelles Co-encapsulating a Brachydin-Enriched Fraction and Curcumin: A Self-assembled Platform for Light-assisted Antileishmanial Activity}},
author = {Ingrid Maria Ribeiro de Lima and Aline Santana Figueredo and Lucilene Amorim Silva and Luciana Magalhães Rebelo Alencar and Cláudia Quintino da Rocha and Renato Sonchini Gonçalves},
journal = {ACS omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c05278},
url = {https://europepmc.org/article/PMC/PMC13670344},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pluronic F127 Micelles Co-encapsulating a Brachydin-Enriched Fraction and Curcumin: A Self-assembled Platform for Light-assisted Antileishmanial Activity
AU - Ingrid Maria Ribeiro de Lima
AU - Aline Santana Figueredo
AU - Lucilene Amorim Silva
AU - Luciana Magalhães Rebelo Alencar
AU - Cláudia Quintino da Rocha
AU - Renato Sonchini Gonçalves
PY - 2026
DA - 2026/10/01
JO - ACS omega
DO - 10.1021/acsomega.6c05278
UR - https://europepmc.org/article/PMC/PMC13670344
AB - This study developed an associative Pluronic F127-based formulation co-loaded with a brachydin-enriched fraction and curcumin (FBC) for preliminary light-assisted antileishmanial evaluation. The formulation showed high apparent active-material recovery after centrifugation and filtration, as estimated by HPLC-PDA. DLS analysis indicated a polydisperse colloidal profile, with an apparent mean hydrodynamic diameter of approximately 406.5 nm and a number-weighted smaller population centered at approximately 12.1 nm. FTIR data were consistent with formulation-related changes in the vibrational environment of the hydrophobic active materials, while AFM and SEM provided complementary morphological information on deposited or dried samples. Together, these data support an interpretative F127-based self-assembly model, without establishing a fully uniform colloidal population or a definitively resolved internal micellar architecture. In vitro cytotoxicity assays using GM07492A human lung fibroblasts indicated low basal cytotoxicity under dark conditions, whereas light exposure produced concentration-dependent viability reductions at higher formulation concentrations. Antileishmanial assays against Leishmania amazonensis promastigotes revealed a marked light-associated response, mainly in formulations containing the brachydin-enriched fraction. FB showed the highest potency under light exposure, with a formulation-based IC50 of 18.63 μg mL–1, whereas FBC showed an IC50 decrease from 72.74 to 34.33 μg mL–1. Thus, although FBC was not more potent than FB, it combined light-associated antileishmanial activity, high apparent active-material recovery, and favorable macroscopic formulation behavior. Because FB and FBC contain a brachydin-enriched fraction rather than purified individual brachydins, the biological responses should be interpreted as preliminary formulation-level effects. Further studies involving direct reactive oxygen species measurements, intracellular amastigote assays, formal selectivity analysis, fraction standardization, and long-term colloidal stability evaluation are still required before therapeutic efficacy can be inferred.
SN - 2470-1343
ER -